Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 29, 2022

BUY
$0.87 - $2.03 $435 - $1,014
500 New
500 $0
Q1 2022

Apr 29, 2022

SELL
$1.46 - $2.48 $730 - $1,240
-500 Closed
0 $0
Q4 2021

Feb 03, 2022

SELL
$2.34 - $5.31 $4,680 - $10,620
-2,000 Reduced 80.0%
500 $1,000
Q3 2021

Oct 21, 2021

BUY
$1.89 - $8.53 $4,725 - $21,325
2,500 New
2,500 $12,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Total Clarity Wealth Management, Inc. Portfolio

Follow Total Clarity Wealth Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Total Clarity Wealth Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Total Clarity Wealth Management, Inc. with notifications on news.